Vittorio Mazzarello, Marco Ferrari, Stefano Decandia, Maria Alessandra Sotgiu: Sunlight and Herpes Virus. In: Ronaldo Luis Thomasini (Hrsg.): Human Herpesvirus Infection – Biological Features, Transmission, Symptoms, Diagnosis and Treatment. IntechOpen, 2020, ISBN 978-1-83881-158-7. doi:10.5772/intechopen.82643
G. Kleymann u. a.: New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. In: Nat. Med. Band8, Nr.4, 2002, S.392–398, doi:10.1038/nm0402-392, PMID 11927946 (nature.com).
V. Mazzarello, M. Ferrari, G. Piu, V. Pomponi, G. Solinas: Do sunscreen prevent recurrent Herpes labialis in summer? In: J Dermatolog Treat. Band 30, Nr. 2, 2019, S. 179–182, doi:10.1080/09546634.2018.1481921.
L. Duteil, C. Queille-Roussel, C. Loesche, M. Verschoore: Assessment of the effect of a sunblock stick in the prevention of solar-simulating ultraviolet light-induced herpes labialis. In: Journal of Dermatological Treatment. Band 9, Nr. 1, 1998, S. 11–14, doi:10.3109/09546639809160682.
A. A. Chentoufi, E. Kritzer, D. M. Yu, A. B. Nesburn, L. Benmohamed: Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. In: Clin. Dev. Immunol. Band2012, 2012, S.187585, doi:10.1155/2012/187585, PMID 22548113, PMC 3324142 (freier Volltext).
W. P. Halford, R. Püschel, E. Gershburg, A. Wilber, S. Gershburg, B. Rakowski: A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. In: PLoS ONE. Band6, Nr.3, 2011, S.e17748, doi:10.1371/journal.pone.0017748, PMID 21412438, PMC 3055896 (freier Volltext).
N. R. Truong, J. B. Smith, K. J. Sandgren, A. L. Cunningham: Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design. In: Frontiers in immunology. Band 10, 2019, S. 373, doi:10.3389/fimmu.2019.00373. PMID 30894859, PMC 6414784 (freier Volltext).
X. Xu, Y. Zhang, Q. Li: Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development. In: Reviews in Medical Virology. Band 29, Nummer 4, Juli 2019, S. e2054, doi:10.1002/rmv.2054. PMID 31197909, PMC 6771534 (freier Volltext).
J. Rajčáni, F. Bánáti, K. Szenthe, S. Szathmary: The potential of currently unavailable herpes virus vaccines. In: Expert review of vaccines. Band 17, Nummer 3, März 2018, S. 239–248, doi:10.1080/14760584.2018.1425620. PMID 29313728.
H. S. De Silva Feelixge, D. Stone, P. Roychoudhury, M. Aubert, K. R. Jerome: CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile? In: ACS infectious diseases. Band 4, Nummer 6, 06 2018, S. 871–880; doi:10.1021/acsinfecdis.7b00273. PMID 29522311, PMC 5993632 (freier Volltext).
B. A. Stanfield, J. Stahl, V. N. Chouljenko, R. Subramanian, A. S. Charles, A. A. Saied, J. D. Walker, K. G. Kousoulas: A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains. In: PLOS ONE. Band9, Nr.10, 2014, S.e109890, doi:10.1371/journal.pone.0109890, PMID 25350288, PMC 4211657 (freier Volltext), bibcode:2014PLoSO...9j9890S.
B. A. Stanfield, B. Pahar, V. N. Chouljenko, R. Veazey, K. G. Kousoulas: Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies. In: Vaccine. Band35, Nr.4, Januar 2017, S.536–543, doi:10.1016/j.vaccine.2016.12.018, PMID 28017425.
B. A. Stanfield, P. J. Rider, J. Caskey, F. Del Piero, K. G. Kousoulas: Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses. In: Vaccine. Band36, Nr.20, Mai 2018, S.2842–2849, doi:10.1016/j.vaccine.2018.03.075, PMID 29655629.
A. L. Richards, P. J. Sollars, J. D. Pitts, A. M. Stults, E. E. Heldwein, G. E. Pickard, G. A. Smith: The pUL37 tegument protein guides alpha-herpesvirus retrograde axonal transport to promote neuroinvasion. In: PLoS Pathogens. Band13, Nr.12, Dezember 2017, Artikel e1006741, doi:10.1371/journal.ppat.1006741, PMID 29216315, PMC 5749899 (freier Volltext).
C. D. Petro, B. Weinrick, N. Khajoueinejad, C. Burn, R. Sellers, W. R. Jacobs, B. C. Herold: HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates. In: JCI Insight. Band1, Nr.12, August 2016, doi:10.1172/jci.insight.88529, PMID 27536733, PMC 4985247 (freier Volltext).
S. Awasthi, L. M. Hook, C. E. Shaw, B. Pahar, J. A. Stagray, D. Liu, R. S. Veazey, H. M. Friedman: An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs. In: PLoS Pathogens. Band13, Nr.1, Januar 2017, Artikel e1006141, doi:10.1371/journal.ppat.1006141, PMID 28103319, PMC 5245903 (freier Volltext).
J. M. Odegard, P. A. Flynn, D. J. Campbell, S. H. Robbins, L. Dong, K. Wang, J. Ter Meulen, J. I. Cohen, D. M. Koelle: A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. In: Vaccine. Band34, Nr.1, Januar 2016, S.101–109, doi:10.1016/j.vaccine.2015.10.137, PMID 26571309, PMC 6322202 (freier Volltext).
K. J. Sandgren, K. Bertram, A. L. Cunningham: Understanding natural herpes simplex virus immunity to inform next-generation vaccine design. In: Clinical & Translational Immunology. Band5, Nr.7, Juli 2016, S.e94, doi:10.1038/cti.2016.44, PMID 27525067, PMC 4973325 (freier Volltext) – (nature.com).
S. Awasthi, E. E. Zumbrun, H. Si, F. Wang, C. E. Shaw, M. Cai, J. M. Lubinski, S. M. Barrett, J. W. Balliet, J. A. Flynn, D. R. Casimiro, J. T. Bryan, H. M. Friedman: Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. In: Journal of Virology. Band86, Nr.8, April 2012, S.4586–4598, doi:10.1128/JVI.07203-11, PMID 22318147, PMC 3318599 (freier Volltext).
S. C. McAllister, M. R. Schleiss: Prospects and perspectives for development of a vaccine against herpes simplex virus infections. In: Expert Review of Vaccines. Band13, Nr.11, November 2014, S.1349–60, doi:10.1586/14760584.2014.932694, PMID 25077372, PMC 4385587 (freier Volltext).
B. A. Stanfield, J. Stahl, V. N. Chouljenko, R. Subramanian, A. S. Charles, A. A. Saied, J. D. Walker, K. G. Kousoulas: A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains. In: PLOS ONE. Band9, Nr.10, 2014, S.e109890, doi:10.1371/journal.pone.0109890, PMID 25350288, PMC 4211657 (freier Volltext), bibcode:2014PLoSO...9j9890S.
Eine Übersicht verschiedener epidemiologischer Studien in B. Halioua, J. E. Malkin: Epidemiology of genital herpes – recent advances. In: Eur J Dermatology. Band 9, Nr. 3, 1999, S. 177–184. PMID 10210781. (Tabelle 2. In: jle.com. Abgerufen am 23. Dezember 2018 (englisch).).
liveherpesvaccine.com
Introducing RVx. 12. März 2016, abgerufen am 2. August 2016 (amerikanisches Englisch).
Herpes Vaccine Research. Herpes Vaccine Research, abgerufen am 2. August 2016 (amerikanisches Englisch).
G. Kleymann u. a.: New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. In: Nat. Med. Band8, Nr.4, 2002, S.392–398, doi:10.1038/nm0402-392, PMID 11927946 (nature.com).
K. J. Sandgren, K. Bertram, A. L. Cunningham: Understanding natural herpes simplex virus immunity to inform next-generation vaccine design. In: Clinical & Translational Immunology. Band5, Nr.7, Juli 2016, S.e94, doi:10.1038/cti.2016.44, PMID 27525067, PMC 4973325 (freier Volltext) – (nature.com).
nih.gov
ncbi.nlm.nih.gov
L. L. Coriell, G. Rake u. a.: Electron microscopy of herpes simplex. In: Journal of Bacteriology. Band 59, Nr. 1, 1950, S. 61–68. PMID 15400321.
K. E. Schneweis, A. J. Nahmias: Antigens of Herpes simplex virus type 1 and 2-immunodiffusion and inhibition passive hemagglutination studies. In: Z. Immunitätsforsch. Exp. Klin. Immunol. Band 141, Nr. 5, 1971, S. 471–487. PMID 4326538.
J. F. Szilágyi, J. Berriman: Herpes simplex virus L particles contain spherical membrane-enclosed inclusion vesicles. In: J. Gen. Virol. Band 75, Nr. 7, 1994, S. 1749–1753. PMID 8021604.
W. Hellenbrand, W. Thierfelder u. a.: Seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in former East and West Germany, 1997–1998. In: Eur. J. Clin. Microbiol. Infect. Dis. Band 24, Nr. 2, 2005, S. 131–135. PMID 15692814.
Eine Übersicht verschiedener epidemiologischer Studien in B. Halioua, J. E. Malkin: Epidemiology of genital herpes – recent advances. In: Eur J Dermatology. Band 9, Nr. 3, 1999, S. 177–184. PMID 10210781. (Tabelle 2. In: jle.com. Abgerufen am 23. Dezember 2018 (englisch).).
C. A. Daniels, S. G. LeGoff: Shedding of infectious virus/antibody complexes from vesicular lesions of patients with recurrent herpes labialis. In: The Lancet. Band 20;2, Nr. 7934, 1975, S. 524–528. PMID 51344.
W. W. Liu, J. Goodhouse, N. L. Jeon, L. W. Enquist: A microfluidic chamber for analysis of neuron-to-cell spread and axonal transport of an alpha-herpesvirus. In: PLoS ONE. Band 18;3, Nr. 6, 2008, Artikel e2382. PMID 18560518PMC 2426917 (freier Volltext).
D. Malvy u. a.: Epidemiology of orofacial herpes simplex virus infections in the general population in France: results of the HERPIMAX study. In: J. Eur. Acad. Dermatol. Venereol. Band 21, Nr. 10, 2007, S. 1398–1403. PMID 17958848.
H. E. Schmidt u. a.: Stress as a pecipitating factor in subjects with recurrent Herpes labialis. In: Journal of Family Practice. Band 20, Nr. 4, April 1985, S. 359–366. PMID 3981095.
M. Ichihashi, H. Nagai, K. Matsunaga: Sunlight is an important causative factor of recurrent herpes simplex. In: Cutis. Band 74, 2004, Supplement 5, S. 14–18. PMID 15603217.
B. Selling, S. Kibrick: An outbreak of Herpes simplex among wrestlers (Herpes gladiatorum). In: New Engl J Med. Band 7, Nr. 270, 1964, S. 979–982. PMID 14122793.
B. J. Anderson: The epidemiology and clinical analysis of several outbreaks of herpes gladiatorum. In: Med. Sci. Sports Exerc. Band 35, Nr. 11, 2003, S. 1809–1814. PMID 14600542.
W. B. White, J. M. Grant-Kels: Transmission of herpes simplex virus type 1 infection in rugby players. In: JAMA. Band 27;252, Nr. 4, 1984, S. 533–535. PMID 6737650.
I. R. Sanderson u. a.: Eczema herpeticum: a potentially fatal disease. In: Br. Med. J. Band 294, Nr. 6573, 1987, S. 693–694. PMID 3105692, PMC 1245744 (freier Volltext).
M. Cordero-Coma u. a.: Herpetic retinitis. (Review) In: Herpes, Band 14, Nr. 1, 2007, S. 4–10; PMID 17848212.
J. Maertzdorf u. a.: Herpes simplex virus type 1 (HSV-1)-induced retinitis following herpes simplex encephalitis: indications for brain-to-eye transmission of HSV-1. In: Ann. Neurol. Band 49, Nr. 1, 2001, S. 104–106. PMID 11198277.
A. Klein, P. Lefebvre: Three consecutive episodes of acute retinal necrosis due to herpes simplex-1 over twelve years following herpetic encephalitis. (Review) In: Ocul. Immunol. Inflamm. Band 15, Nr. 5, 2007, S. 411–413. PMID 17972228.
S. Murakami u. a.: Bell’s palsy and herpes simplex virus: Identification of viral DNA in endoneurial fluid and muscle. In: Ann Intern Med. Band 124, Nr. 1, 1996, S. 27–30. PMID 7503474.
H. Wakisaka u. a.: Demyelination associated with HSV-1-induced facial paralysis. In: Exp. Neurol. Band 178, Nr. 1, 2002, S. 68–79. PMID 12460609.
Eine Übersicht der HSV-Ösophagitiden in: K. Becker, H. J. Lübke, F. Borchard, D. Häussinger: Entzündliche Speiseröhrenerkrankungen durch Herpes-simplex-Virusinfektionen – Übersicht und Bericht über 15 eigene Fälle. In: Z. Gastroenterol. Band 34, Nr. 5, 1996, S. 286–295. PMID 8686361.
J. Ramanathan u. a.: Herpes simplex virus esophagitis in the immunocompetent host: an overview. In: Am. J. Gastroenterol. Band 95, Nr. 9, 2000, S. 2171–2176. PMID 11007213.
G. Biancofiore u. a.: Liver transplantation due to Herpes Simplex virus-related sepsis causing massive hepatic necrosis after thoracoscopic thymectomy. In: Minerva Anestesiol. Band 73, Nr. 5, 2007, S. 319–322. PMID 17529922.
N. J. Schmidt, B. Forghani, E. H. Lennette: Type specificity of complement-requiring and immunoglobulin M neutralizing antibody in initial herpes simplex virus infections of humans. In: Infect Immun. Band 12, Nr. 4, 1975, S. 728–732. PMID 1193713, PMC 415348 (freier Volltext).
K. E. Ostheimer u. a.: Randomized double-blind trial of tromantadine versus aciclovir in recurrent herpes orofacialis. In: Arzneimittel-Forschung, Band 39, Nr. 9, 1989, S. 1152–1155. PMID 2686658.
M. R. Holdiness: Contact dermatitis from topical antiviral drugs. In: Contact Dermatitis. Band 44, Nr. 5, 2001, S. 265–269. PMID 11298689.
G. Kleymann u. a.: New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. In: Nat. Med. Band8, Nr.4, 2002, S.392–398, doi:10.1038/nm0402-392, PMID 11927946 (nature.com).
D. J. Freeman u. a.: Treatment of recurrent herpes simplex labialis with topical butylated hydroxytoluene. In: Clin Pharmacol Ther. Band 38, Nr. 1, 1985, S. 56–59. PMID 2988845.
M. W. Grogan: Toxicity from BHT ingestion. In: West J Med. Band 145, Nr. 2, 1986, S. 245–246, PMC 1306899 (freier Volltext).
A. A. Chentoufi, E. Kritzer, D. M. Yu, A. B. Nesburn, L. Benmohamed: Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. In: Clin. Dev. Immunol. Band2012, 2012, S.187585, doi:10.1155/2012/187585, PMID 22548113, PMC 3324142 (freier Volltext).
W. P. Halford, R. Püschel, E. Gershburg, A. Wilber, S. Gershburg, B. Rakowski: A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. In: PLoS ONE. Band6, Nr.3, 2011, S.e17748, doi:10.1371/journal.pone.0017748, PMID 21412438, PMC 3055896 (freier Volltext).
N. R. Truong, J. B. Smith, K. J. Sandgren, A. L. Cunningham: Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design. In: Frontiers in immunology. Band 10, 2019, S. 373, doi:10.3389/fimmu.2019.00373. PMID 30894859, PMC 6414784 (freier Volltext).
X. Xu, Y. Zhang, Q. Li: Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development. In: Reviews in Medical Virology. Band 29, Nummer 4, Juli 2019, S. e2054, doi:10.1002/rmv.2054. PMID 31197909, PMC 6771534 (freier Volltext).
J. Rajčáni, F. Bánáti, K. Szenthe, S. Szathmary: The potential of currently unavailable herpes virus vaccines. In: Expert review of vaccines. Band 17, Nummer 3, März 2018, S. 239–248, doi:10.1080/14760584.2018.1425620. PMID 29313728.
H. S. De Silva Feelixge, D. Stone, P. Roychoudhury, M. Aubert, K. R. Jerome: CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile? In: ACS infectious diseases. Band 4, Nummer 6, 06 2018, S. 871–880; doi:10.1021/acsinfecdis.7b00273. PMID 29522311, PMC 5993632 (freier Volltext).
B. A. Stanfield, J. Stahl, V. N. Chouljenko, R. Subramanian, A. S. Charles, A. A. Saied, J. D. Walker, K. G. Kousoulas: A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains. In: PLOS ONE. Band9, Nr.10, 2014, S.e109890, doi:10.1371/journal.pone.0109890, PMID 25350288, PMC 4211657 (freier Volltext), bibcode:2014PLoSO...9j9890S.
B. A. Stanfield, B. Pahar, V. N. Chouljenko, R. Veazey, K. G. Kousoulas: Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies. In: Vaccine. Band35, Nr.4, Januar 2017, S.536–543, doi:10.1016/j.vaccine.2016.12.018, PMID 28017425.
B. A. Stanfield, P. J. Rider, J. Caskey, F. Del Piero, K. G. Kousoulas: Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses. In: Vaccine. Band36, Nr.20, Mai 2018, S.2842–2849, doi:10.1016/j.vaccine.2018.03.075, PMID 29655629.
A. L. Richards, P. J. Sollars, J. D. Pitts, A. M. Stults, E. E. Heldwein, G. E. Pickard, G. A. Smith: The pUL37 tegument protein guides alpha-herpesvirus retrograde axonal transport to promote neuroinvasion. In: PLoS Pathogens. Band13, Nr.12, Dezember 2017, Artikel e1006741, doi:10.1371/journal.ppat.1006741, PMID 29216315, PMC 5749899 (freier Volltext).
C. D. Petro, B. Weinrick, N. Khajoueinejad, C. Burn, R. Sellers, W. R. Jacobs, B. C. Herold: HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates. In: JCI Insight. Band1, Nr.12, August 2016, doi:10.1172/jci.insight.88529, PMID 27536733, PMC 4985247 (freier Volltext).
S. Awasthi, L. M. Hook, C. E. Shaw, B. Pahar, J. A. Stagray, D. Liu, R. S. Veazey, H. M. Friedman: An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs. In: PLoS Pathogens. Band13, Nr.1, Januar 2017, Artikel e1006141, doi:10.1371/journal.ppat.1006141, PMID 28103319, PMC 5245903 (freier Volltext).
J. M. Odegard, P. A. Flynn, D. J. Campbell, S. H. Robbins, L. Dong, K. Wang, J. Ter Meulen, J. I. Cohen, D. M. Koelle: A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. In: Vaccine. Band34, Nr.1, Januar 2016, S.101–109, doi:10.1016/j.vaccine.2015.10.137, PMID 26571309, PMC 6322202 (freier Volltext).
K. J. Sandgren, K. Bertram, A. L. Cunningham: Understanding natural herpes simplex virus immunity to inform next-generation vaccine design. In: Clinical & Translational Immunology. Band5, Nr.7, Juli 2016, S.e94, doi:10.1038/cti.2016.44, PMID 27525067, PMC 4973325 (freier Volltext) – (nature.com).
S. Awasthi, E. E. Zumbrun, H. Si, F. Wang, C. E. Shaw, M. Cai, J. M. Lubinski, S. M. Barrett, J. W. Balliet, J. A. Flynn, D. R. Casimiro, J. T. Bryan, H. M. Friedman: Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. In: Journal of Virology. Band86, Nr.8, April 2012, S.4586–4598, doi:10.1128/JVI.07203-11, PMID 22318147, PMC 3318599 (freier Volltext).
S. C. McAllister, M. R. Schleiss: Prospects and perspectives for development of a vaccine against herpes simplex virus infections. In: Expert Review of Vaccines. Band13, Nr.11, November 2014, S.1349–60, doi:10.1586/14760584.2014.932694, PMID 25077372, PMC 4385587 (freier Volltext).
Immune Design Pipeline. Immune Design, archiviert vom Original (nicht mehr online verfügbar) am 11. Mai 2019; abgerufen am 22. April 2017.
GV2207 – HSV-2 Immunotherapeutic. In: genvec.com. GenVec, Inc. (GNVC), archiviert vom Original (nicht mehr online verfügbar) am 9. Dezember 2017; abgerufen am 16. August 2016.
PBS Vax™ Therapeutic Vaccines. In: profectusbiosciences.com. Archiviert vom Original (nicht mehr online verfügbar) am 23. Mai 2019; abgerufen am 15. August 2016.
Immune Design Pipeline. Immune Design, archiviert vom Original (nicht mehr online verfügbar) am 11. Mai 2019; abgerufen am 22. April 2017.
GV2207 – HSV-2 Immunotherapeutic. In: genvec.com. GenVec, Inc. (GNVC), archiviert vom Original (nicht mehr online verfügbar) am 9. Dezember 2017; abgerufen am 16. August 2016.
PBS Vax™ Therapeutic Vaccines. In: profectusbiosciences.com. Archiviert vom Original (nicht mehr online verfügbar) am 23. Mai 2019; abgerufen am 15. August 2016.
P. G. Unna. In: J. cutan. vener. Dis. Band 1, 1883, S. 321, zugänglich in: J. K. Oates: Venereal disease genital herpes. In: Journal of Hospital Medicine. Band 6, 1983, ISSN1553-5606, S. 13–19.
H. B. Slavin, E. Gavett: Primary herpetic vulvovaginitis. In: Proceedings of the Society for Experimental Biology and Medicine. Band 63, 1946, ISSN1525-1373, S. 343.